PDS Biotechnology Corp at Noble Capital Markets Takeaway Series on Channelchek- J.P. Morgan Healthcare Conference Transcript
Welcome to the Channelchek Takeaway Series. This program is provided for informational purposes only, and none of its content should be interpreted as a recommendation or solicitation to buy or sell securities. Investment decisions must be made by you or with the support of your financial advisor. The complete disclosure statement follows each presentation.
PDS Biotechnology, NASDAQ ticker symbol, PDSB. is a clinical-stage immunotherapy company, developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on their proprietary Versamune and Infectimune T cell-activating technology platforms. Joining us today is PDS Biotech President and CEO, Frank Bedu-Addo. Following a discussion of the company pipeline, Frank is joined by Noble's senior research analysts, Robert LeBoyer, for Q&A. And now, here's Robert and Frank.
With me here today is Dr. Frank Bedu-Addo, President and CEO of PDS Biotech. Biotechnology industry has gone through a long decline, probably the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |